1. CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice
- Author
-
Agata Sasor, Jakub Golab, Koryna Socha, Dominika Nowis, Magdalena Stoksik, Piotr J. Wysocki, Ahmad Jalili, Witold Lasek, Marek Jakóbisiak, Grzegorz W. Basak, Nadzieja Drela, Tomasz Switaj, Andrzej Mackiewicz, and Anna Jakubowska
- Subjects
Cancer Research ,Time Factors ,medicine.medical_treatment ,Melanoma, Experimental ,Oligonucleotides ,Tetrazolium Salts ,Antineoplastic Agents ,Enzyme-Linked Immunosorbent Assay ,Biology ,Cancer Vaccines ,Melanoma Vaccine ,Interferon-gamma ,Mice ,Immune system ,Cell Line, Tumor ,medicine ,Cytotoxic T cell ,Animals ,Humans ,Melanoma ,Fluorescent Dyes ,Macrophages ,Histocompatibility Antigens Class II ,Interleukin ,DNA ,Th1 Cells ,medicine.disease ,Flow Cytometry ,Interleukin-12 ,Mice, Inbred C57BL ,Thiazoles ,Oncology ,Oligodeoxyribonucleotides ,Tumor progression ,Lymphatic Metastasis ,Immunology ,Cancer research ,Interleukin 12 ,Disease Progression ,Cytokines ,CpG Islands ,Adjuvant ,Spleen - Abstract
Purpose: The effectiveness of interleukin (IL)-12-secreting tumor vaccines in the treatment of mouse tumors could be enhanced by concurrent application of cytokines and costimulatory molecules. We investigated the therapeutic potential of IL-12 gene-transduced melanoma vaccine in combination with CpG immunostimulatory oligodeoxynucleotide (ODN) 1826, an adjuvant known to favor development of Th1-biased immune response, in a B78-H1 (B78) melanoma model in mice. Experimental Design: Mice injected with B78 melanoma cells were treated with irradiated IL-12 gene-transduced B78 cells [B78/IL-12(X)] and/or ODN 1826. Mechanisms responsible for the antitumor effects of the treatment were investigated using fluorescence-activated cell sorter analysis, a standard 51Cr releasing assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and ELISA. Results: Single injection of B78/IL-12(X) cells had no effect on tumor growth, whereas seven consecutive daily injections of ODN 1826 markedly inhibited tumor progression with occasional curative effects. When used in combination, B78/IL-12(X) cells and ODN 1826 caused additional tumor growth reduction and eradication of tumors in 62% of treated mice. The combined treatment activated local inflammatory response against tumor but also induced systemic antitumor immunity. In vitro studies have shown that when used together, B78/IL-12(X) cells and ODN 1826 induced a potent Th1 response and suggested the role of IFN-γ in activation of the host immune response. The antitumor effects in double-treated mice were accompanied by the development of cytotoxic effectors in the spleen and activation of macrophages. Conclusions: The results provided the evidence that the combination of IL-12 gene-modified melanoma vaccine and ODN 1826 induces synergistically systemic and local antitumor immunity.
- Published
- 2004